AMY-101
As of the edition of 20 October 2026, AMY-101 is a protein: in active development; acts on C3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2021
- Kind
- Protein
- Registered trials
- 2, 0 stopped early
- Disease areas
- Blood and lymph; Eye; Infections; Lungs and airways; Mouth and teeth
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| C3 | Complement C3 | P01024 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 1 | 0 | 0 | 0 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Amyndas Pharmaceuticals | Lead sponsor of trials | 2017 to now |